From Wikipedia, the free encyclopedia
Clinical data
Other namesU-7265; 5α-Dihydrofluoxymesterone; 9α-Fluoro-11β-hydroxy-17α-methyl-5α-dihydrotestosterone; 9α-Fluoro-11β-hydroxy-17α-methyl-5α-DHT; 9α-Fluoro-11β-hydroxy-17α-methyl-5α-androstan-17β-ol-3-one
Routes of
By mouth
Drug classAndrogen; Anabolic steroid
Chemical and physical data
Molar mass337.455 g·mol−1
3D model (JSmol)
  • [H][C@@]12CC[C@](C)(O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2CC(=O)CC[C@]12C
  • InChI=1S/C20H30FO3/c1-17-8-6-13(22)10-12(17)4-5-15-14-7-9-19(3,24)18(14,2)11-16(23)20(15,17)21/h12,14-15,23-24H,4-11H2,1-3H3/t12-,14-,15-,17-,18-,19-,20-/m0/s1

Dihydrofluoxymesterone (developmental code name U-7265) is an androgen and anabolic steroid (AAS) which was never marketed.[1][2][3] It was assessed in the treatment of breast cancer in women in at least one clinical study in the 1970s and showed effectiveness similar to that of other AAS.[1][2] The drug is the 5α-reduced analogue and metabolite of fluoxymesterone.[1][2][3]

See also[edit]


  1. ^ a b c Gordan, G. S. (1976). "Cancer in Man". Anabolic-Androgenic Steroids. pp. 499–513. doi:10.1007/978-3-642-66353-6_16. ISBN 978-3-642-66355-0.
  2. ^ a b c Charles D. Kochakian (6 December 2012). Anabolic-Androgenic Steroids. Springer Science & Business Media. pp. 504–. ISBN 978-3-642-66353-6.
  3. ^ a b Kammerer RC, Merdink JL, Jagels M, Catlin DH, Hui KK (1990). "Testing for fluoxymesterone (Halotestin) administration to man: identification of urinary metabolites by gas chromatography-mass spectrometry". J. Steroid Biochem. 36 (6): 659–66. doi:10.1016/0022-4731(90)90185-u. PMID 2214783.